Related Experiment Videos
Clinical use of intrapulmonary heparin
Seminars in Thrombosis and Hemostasis
|April 1, 1985
Summary
Intrapulmonary heparin shows high efficacy and safety for preventing deep vein thrombosis and thromboembolic disease. This novel outpatient therapy offers a superior alternative to existing treatments with a low recurrence rate.
Area of Science:
- Pulmonary Medicine
- Hematology
- Pharmacology
Background:
- Deep vein thrombosis (DVT) and thromboembolic disease (TED) are significant health concerns.
- Current long-term outpatient prophylaxis options have limitations in efficacy and safety.
Purpose of the Study:
- To evaluate the safety and efficacy of intrapulmonary heparin for DVT and TED prophylaxis.
- To explore the potential of home-based aerosolized heparin therapy.
Main Methods:
- 16 patients received intrapulmonary heparin (10,000–20,000 U/week) for 1592 patient-days.
- Patient history of thrombotic events was analyzed before and during therapy.
Main Results:
- Only one patient (with antithrombin III deficiency) rethrombosed, representing a 1.4% annual recurrence rate.
- This rate is significantly lower than warfarin or antiplatelet therapies.
- Intrapulmonary heparin demonstrated remarkable safety and effectiveness in reducing thrombotic events.
Conclusions:
- Intrapulmonary heparin is a safe and highly effective outpatient prophylactic treatment for DVT and TED.
- Home-use aerosolized heparin offers a convenient, safe, and efficacious long-term therapeutic option.